Zócalo Health | $15,000,000 | (Apr 24, 2026)
Rilian | $17,500,000 | (Apr 24, 2026)
BAND | $17,000,000 | (Apr 24, 2026)
Carthera
France
- PARIS, IDF
- 27/06/2023
- Series B
- $41,077,875
Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders.
Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain.
By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS).
The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.
- Industry Medical Equipment Manufacturing
- Website https://carthera.eu/
- LinkedIn https://www.linkedin.com/company/carthera/
Brev.io | $3,300,000 | (Apr 24, 2026)
Maxed | $850,000 | (Apr 24, 2026)
Omni | $120,000,000 | (Apr 24, 2026)
VREY | $3,859,432 | (Apr 24, 2026)
Astor (YC S25) | $5,000,000 | (Apr 24, 2026)
QMatter | $1,200,000 | (Apr 24, 2026)
Almanac Health | $10,000,000 | (Apr 24, 2026)
Petual | $20,000,000 | (Apr 24, 2026)
C-Infinity | $16,000,000 | (Apr 23, 2026)